布地奈德福莫特罗吸入治疗对慢阻肺合并肺癌稳定期患者的疗效及价值分析

汪雨珠

【摘要】 目的：分析布地奈德福莫特罗吸入治疗在慢阻肺合并肺癌稳定期患者中的疗效和应用价值。方法：选取2016年3月-2018年2月本院收治的慢阻肺合并肺癌稳定期患者50例。按照随机数字表法将其分为对照组和观察组，各25例。对照组给予对症治疗+基础治疗，观察组给予对症治疗+基础治疗+布地奈德福莫特罗吸入治疗。比较两组比较肺功能指标（FEV1/FVC、FEV1%）、不良反应、生活质量评分。结果：疗程结束后，两组FEV1/FVC、FEV1%均高于治疗前，且观察组均优于对照组，差异均有统计学意义（P<0.05）;两组不良反应发生率比较，差异无统计学意义（P>0.05）;疗程结束后，两组生活质量评分均高于治疗前，且观察组高于对照组，差异均有统计学意义（P<0.05）。结论：慢阻肺合并肺癌稳定期患者在基础和对症治疗外，吸入布地奈德福莫特罗粉，可改善预后。

【关键词】 慢阻肺; 肺癌; 稳定期; 布地奈德福莫特罗

【Abstract】 Objective：To analyze the efficacy and application value of Budesonide Formoterol inhalation in COPD patients with stable lung cancer.Method：A total of 50 COPD patients with stable lung cancer from March 2016 to February 2018 in our hospital were selected.According to the random number table method，they were divided into control group and observation group，25 cases in each group.The control group was given symptomatic treatment+basic treatment，while the observation group was given symptomatic treatment+basic treatment+Budesonide Formoterol inhalation treatment.The lung function indexes（FEV1/FVC，FEV1%），adverse reactions and quality of life scores between two groups were compared.Result：At the end of the course，the FEV1/FVC and FEV1% of two groups were higher than those of before treatment，and observation group were better than those of control group，the differences were statistically significant（P<0.05）.The incidence of adverse reactions in two groups was compared，the difference was statistically significant（P>0.05）.After the end of the treatment，the total quality of life scores of two groups were higher than those of before treatment，and observation group was higher than that of control group，the differences were statistically significant（P<0.05）.Conclusion：In addition to basic and symptomatic treatment，Budesonide Formoterol inhalation treatment can improve the prognosis of COPD patients with stable lung cancer.

【Key words】 Chronic obstructive pulmonary disease; Lung cancer; Stable; Budesonide Formotero

First-authors address：Jian Central Peoples Hospital，Jian 343000，China

doi：10.3969/j.issn.1674-4985.2019.08.030

慢性阻塞性肺疾病（慢阻肺）高發于中老年人[1]，因其症状表现无特异性，加上很多患者对其不够重视，容易耽误治疗，而此病有引发肺癌的风险[2]，故目前临床上慢阻肺合并肺癌的病例较多，疾病得以控制后，进入稳定期，此阶段注重症状的改善与生活质量的提高。布地奈德福莫特罗属于混合制剂，通过吸入方式给药，舒适度高，药效最大程度上发挥[3-5]，本文为了分析布地奈德福莫特罗吸入治疗在慢阻肺合并肺癌稳定期患者中的疗效和应用价值，选取患者50例进行研究。现报道如下。

1 资料与方法

1.1 一般资料 选取2016年3月-2018年2月本院收治的慢阻肺合并肺癌稳定期患者50例。纳入标准：符合疾病诊断标准，有组织病理学诊断资料;处于稳定期;年龄40～75岁。排除标准：合并其他严重性呼吸系统疾病，如支气管扩张、支气管哮喘、阻塞性肺炎等;其他重要脏器存在功能性障碍;研究过程中的3个月，慢阻肺急性加重;伴发精神疾病或存在认知功能障碍。……